Warngau, February 07, 2023
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor for Drug Delivery in the Department of Pharmacy at Ludwig-Maximilians-Universität (LMU) Munich, Germany, as a member to AMW’s Scientific Advisory Board (SAB). Prof. Merkel is an internationally renowned expert in novel and targeted drug delivery systems, including RNA delivery systems. Her appointment will further broaden AMW’s scientific expertise in sustained-release systems, such as biodegradable implants, and contribute to the Company’s strategic development plans. With her appointment, Prof. Merkel will succeed Prof. Dr. Gerhard Winter, who will step down from his position on the SAB.
“We are excited to welcome Professor Merkel to our SAB,” said Dr. Konstantin Petropoulos, CEO of AMW. “Building on her invaluable scientific and medical expertise, she will support our strategic path to develop innovative sustained-release drug delivery systems for patients worldwide. We very much look forward to our cooperation and exchange. Furthermore, I would like to express my sincere thanks to Professor Winter for his great contribution since the Board’s foundation three years ago. Drawing on the SAB members’ experience and knowledge was instrumental to raise our profile and will continue to support us in pursuing our growth strategy.”
Prof. Dr. Olivia Merkel has been Professor of Drug Delivery at LMU Munich since 2015. She served as President of the Controlled Release Society, German Local Chapter, from 2020 to 2021, and as Chair of the CRS Focus Group Transdermal and Mucosal Delivery from 2020 to 2022. During her scientific career, Prof. Merkel led research laboratories in Germany and the U.S. and was a reviewer for the NIH (National Institutes for Health) from 2014 to 2015. From 2018 to 2022, she was a permanent international member of the Review Board of the Swiss National Science Foundation. She is a member of the Editorial Board for the Journal of Controlled Release, the European Journal of Pharmaceutics and Biopharmaceutics, Molecular Pharmaceutics, Advanced NanoBiomed Research, Pharmaceutics, Acta Pharmaceutica Sinica B, and an honorary member of the Académie des Alpilles.
AMW GmbH is a specialty pharmaceutical company focused on biodegradable sustained-release drug delivery systems, providing patients and partners access to value-added medicines and cost-effective therapies. Based on its technology platform, the Company builds on a growing own and partnered development pipeline. AMW has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners. In Germany, leuprorelin is marketed as Leugon® by AMW’s wholly owned subsidiary Endomedica GmbH. To support pharma and biotech partners in the development and manufacturing of their products and life-cycle solutions, AMW uses its leading-edge formulation development expertise.
AMW is based in Warngau near Munich, Germany.
For further information please contact:
Dr. Konstantin Petropoulos
Phone: +49 8024 470999-0 E-mail: firstname.lastname@example.org